



Press release

Oncology Venture prolongs subscription period

Hørsholm, Denmark April 30, 2019 – Oncology Venture A/S has decided to extent the subscription period in current rights issue.

Rights issue

In light of the clinical news published in press release today April 30, 2019 “*Oncology Venture provides news on its clinical development projects dovitinib, 2X-121 and LiPlaCis*”, the board of directors in Oncology Venture A/S has decided to extent the subscription period in the rights issue until May 10, 2019. Trading in subscription rights will resume Friday May 3, 2019 and the last day of trading subscription rights will be May 8, 2019.

A prospectus supplement will be published once approved by the Danish Financial Supervisory Authority, expectedly May 1, 2019 or May 2, 2019.

For further information, please contact:

For investor inquiries

Ulla Hald Buhl

IR & Communications

E-mail: uhb@oncologyventure.com

Telephone +45 21 70 10 49

For media inquiries

Thomas Pedersen

Carrotize PR & Communications

E-mail: tsp@carrotize.com

Telephone +45 60 62 93 90

About Oncology Venture A/S

Oncology Venture A/S is engaged in the research and development of anti-cancer drugs via its wholly-owned subsidiary, Oncology Venture Product Development ApS. Oncology Venture uses Drug Response Prediction – DRP® –to significantly increase the probability of success in clinical trials. DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 29 out of 37 clinical studies that were examined and is currently demonstrating promising results in an ongoing phase 2 study prospectively using LiPlaCis and its DRP® to track, match and treat patients with metastatic breast cancer. The DRP® alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are first screened, and only the patients most likely to respond to the treatment will be treated. Via a more well-defined patient group, risks and costs are reduced while the development process becomes more efficient.

The current OV product portfolio includes: LiPlaCis®, a liposomal formulation of cisplatin in an ongoing Phase 2 trial for breast and prostate cancer; 2X-121 a PARP inhibitor in an ongoing Phase 2 for breast cancer; dovitinib, which will enter Phase 2 trials for indications dependent on further Dovitinib-DRP retrospective/prospective analysis of studies completed by Novartis. 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer; irofulven, a Phase 2 is ongoing for prostate cancer; and APO010, an immuno-oncology product in Phase 1/2 for multiple myeloma.

Oncology Venture has spun out two companies as Special Purpose Vehicles: Oncology Venture U.S. Inc. (previously 2X Oncology Inc.), a US-based precision medicine company focusing on developing 2X-121 and 2X-111, and OV-SPV 2, a Danish company that will test and develop dovitinib. Oncology Venture A/S has an ownership of 92% in Oncology Venture US and 55% of dovitinib with an opportunity to acquire further 30%.

Learn more at oncologyventure.com

Follow us on social media:

Facebook: <https://www.facebook.com/oncologyventure/>

LinkedIn: <https://www.linkedin.com/company/oncology-venture/>

Twitter: <https://twitter.com/OncologyVenture>

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OV's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OV's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OV undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Certified Adviser: Sedermera Fondkommission. Epost: ca@sedermera.se, telefon 040-615 14 10